The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAmid a landscape defined by market resilience against geopolitical friction, Nasdaq futures surged 190 points as US markets steadied despite renewed flare-ups in the Gulf region. The positive momentum was partly supported by PepsiCo, which reported earnings that narrowly beat estimates due to international strength, offsetting sluggish sales in North America. However, the broader market sentiment remains mixed as AstraZeneca shares fell following disappointing heart drug trial results, and Levi Strauss dropped on the back of weak forward guidance.
This divergence highlights ongoing volatility in the consumer and healthcare sectors, with PEP closing at $142.51 and LEVI at $24.37 per market data on July 8, 2026. In comparison to industry peers, PepsiCo's international performance remains a key differentiator, especially as competitors like Coca-Cola navigate similar inflationary pressures. Meanwhile, the clinical setback for AstraZeneca weighed heavily on its valuation, with the stock closing at $178.49 on July 9, 2026, failing to maintain its daily high of $180.22.
Investors should watch for Nasdaq's ability to maintain these pre-market gains as the session opens, particularly with energy price volatility linked to geopolitical risks. According to the economic calendar, there are no immediate high-impact US catalysts scheduled for the next 24 hours, leaving corporate earnings and geopolitical headlines as the primary drivers. With AZN closing at $178.49 on July 9, 2026, market participants will be looking to see if the stock finds support near its recent daily low of $173.36.